-
In this issue: Apixaban approval; new dental clinical practice guideline; apixaban for VTE; aspirin resistance; tamoxifen treatment; and FDA actions.
-
Based on the prior work of patrick kwan and martin brodie, The efectiveness of the first antiepileptic drug (AED) in new-onset epilepsy is nearly 50%.
-
Dr. Henchcliffe reports she is on the speakers bureau and advisory board for Allergan and Teva; speakers bureau for Boehringer-Ingelheim, GlaxoSmith-Kline, and Novartis; advisory board for Merz; and is a consultant for Gerson Lehman Group and Guidepoint Global.
-
Treatment and Outcome after Acute Cervical Artery Occlusion with Stroke; Continuous Transcranial Doppler Insonation Can Determine Recanalization Following Acute Ischemic Stroke; Antithrombotic Therapy Appears to be Safe for Patients with Cerebral Cavernous Malformations
-
Zolpidem and risk of falls; AVR and anticoagulation; statins in cancer patients; and FDA actions.
-
Cholinergic system dysfunction, as measured by short latency afferent inhibition, might contribute to gait abnormality in early stages of Parkinsons disease.
-
Use of dexamethasone in community-acquired bacterial meningitis is associated with long-term survival in treated patients.
-
Video-oculography reveals spontaneous or gaze-evoked nystagmus in more than a quarter of patients with isolated superior cerebellar infarction.
-
A novel target for suppression of cortical spreading depression shows promise in rodent models and in patients with medically refractory migraine with aura.
-
Repetitive nerve stimulation studies appear to be safe in patients with modern implantable pacemakers and defibrillators.
